secwatch.observer — SEC 8-K summary
======================================

Issuer:     Co-Diagnostics, Inc. (CODX)
CIK:        0001692415
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001493152-24-044001
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Co-Diagnostics Q3 revenue $0.6M down from $2.5M; net loss $9.7M ($0.32/share)
-----------------------------------------------------------------------------

- Q3 2024 revenue $0.6M ($0.4M grant + $0.2M product) vs $2.5M prior year, down 76%.
- Net loss $9.7M ($0.32 per diluted share) vs $6.0M ($0.20) prior year; operating loss $10.2M.
- Adjusted EBITDA loss $8.8M; cash and securities $37.7M as of Sept 30, 2024.
- FDA 510(k) review ongoing for Co-Dx PCR platform; TB, respiratory, HPV multiplex tests in pipeline.
- India oligonucleotide (Co-Primers) mfg facility inauguration expected early Dec 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1692415/000149315224044001/0001493152-24-044001-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1692415/000149315224044001/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-044001

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer